spec sheet9 rows
alpha-conotoxin pia is a cone-snail (conus purpurascens) peptide toxin and the first ligand able to cleanly discriminate alpha6- from alpha3-containing nicotinic receptors; a highly alpha6beta2*-selective research probe that sharpened the interpretation of 'mii-sensitive' dopamine and gaba experiments; a lab reagent, not a drug.
- the first ligand able to discriminate alpha6- from alpha3-containing nicotinic receptors
- highly alpha6beta2*-selective; a precision probe that sharpened every 'MII-sensitive' experiment
- spares muscle and alpha4beta2 receptors
- part of the conotoxin toolkit (with MII and TxIB) that defined alpha6* dopamine-terminal pharmacology
Mechanism
alpha-conotoxin pia is a toxin cloned from the venom of the cone snail conus purpurascens, and its place in the alpha6 story is specific and important: it was the first that could tell alpha6-containing receptors apart from the very closely related alpha3-containing ones. according to pubmed, dowell et al showed pia potently and competitively blocks the chimeric alpha6/alpha3beta2beta3 receptor expressed in oocytes while leaving the muscle receptor and the major neuronal alpha4beta2 subtype essentially untouched, and they emphasized that it was the first described ligand to discriminate between receptors containing alpha6 versus alpha3 subunits (doi 10.1523/jneurosci.23-24-08445.2003). this mattered because the older founding probe, alpha-conotoxin mii, blocks both alpha3beta2 and alpha6* receptors with high affinity, so 'mii-sensitive' could never by itself prove alpha6 involvement. pia added the missing resolution. its practical value as a discriminator is well illustrated in a superior colliculus study where mii blocked a substantial fraction of nicotinic release but the highly alpha6-selective pia did not, leading the authors to conclude the mii-sensitive receptor there was actually a novel alpha3-containing (not alpha6) subtype (mcclure-begley et al 2012, doi 10.1111/j.1471-4159.2012.07759.x). used alongside the engineered mii analogs, txib and alpha6-knockout mice, pia is part of the toolkit that established alpha6beta2* receptors as a distinct, -associated population that gates nicotine-evoked dopamine and represents a candidate target for smoking-cessation and parkinson's drugs. the honest framing is the same as for the rest of the family: pia is a precision research reagent, not a therapeutic; peptide conotoxins are difficult to develop into drugs, and pia's contribution is the clean alpha6-versus-alpha3 discrimination that helped make alpha6* a well-defined target in the first place.
receptor fingerprint
Alpha6/alpha3beta2beta3 (a6*)competitive antagonist
Alpha6 vs alpha3 discriminationdistinguishes (first ligand to do so)
Alpha4beta2 (a4b2)little/no block
Muscle receptorlittle/no block
Safetyrisks and cautions, not medical advice
Alpha-Conotoxin PIA is a cone-snail venom peptide used strictly as a laboratory probe for alpha6-containing nicotinic acetylcholine receptors; there is no clinical safety data in humans because it has never been developed as a therapeutic. As a selective nAChR antagonist it blocks cholinergic signaling, and conotoxins as a class are potent neuroactive venom components, so any systemic exposure would carry theoretical risk to autonomic and neuromuscular function, but no documented human toxicity profile exists. Being a disulfide-bridged peptide it is not orally bioavailable and would be degraded in the gut, which limits casual exposure. It should be treated as a research reagent, not a consumable, and the honest position is that its human risk profile is simply uncharacterized. No trials, labels, or established side-effect data are available.
Subjective profileweighing the evidence above
A laboratory reagent and nothing else. Its value is that it can cleanly tell alpha6 nicotinic receptors from alpha3, which sharpened a whole literature. There is no therapeutic use, no human data, and no reason for anyone outside a lab to handle a cone-snail venom peptide.
Resources
This entry is here for reference.
Research
- 2003first citedAlpha-conotoxin PIA is selective for alpha6 subunit-containing nicotinic acetylcholine receptors
- 2012most recentA novel α-conotoxin MII-sensitive nicotinic acetylcholine receptor modulates [(3) H]-GABA relea…
- 1.Alpha-conotoxin PIA is selective for alpha6 subunit-containing nicotinic acetylcholine receptors
- 2.A novel α-conotoxin MII-sensitive nicotinic acetylcholine receptor modulates [(3) H]-GABA release in the superficial layers of the mouse superior colliculus.
- 3.Striatal alpha6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy
3 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
what is alpha-conotoxin pia?
it's a peptide toxin cloned from the cone snail conus purpurascens, and its claim to fame is being the first ligand that could actually tell alpha6-containing nicotinic receptors apart from the very similar alpha3-containing ones. according to pubmed, dowell et al reported it potently blocks the chimeric alpha6/alpha3beta2beta3 receptor but not the muscle or major neuronal alpha4beta2 subtype, and, crucially, it was the first toxin to discriminate between alpha6 and alpha3 receptors (doi 10.1523/jneurosci.23-24-08445.2003).
why was distinguishing alpha6 from alpha3 such a big deal?
because the two subunits are so closely related that the older workhorse toxin, alpha-conotoxin mii, blocked both without cleanly separating them. that ambiguity clouded every experiment that used 'mii-sensitive' as a readout. pia gave the field a sharper knife, letting researchers attribute effects specifically to alpha6* receptors, which is exactly what you need when alpha6* is the dopamine-terminal receptor you care about for nicotine reward and parkinson's.
how selective is it, really?
quite; it's routinely described as 'highly alpha6beta2*-selective'. in practice researchers use pia precisely because it separates alpha6* function from alpha3* and alpha4beta2 function. a nice illustration: in a superior colliculus study, alpha-conotoxin mii blocked a chunk of gaba release but the highly alpha6-selective pia did not, which told the authors that the mii-sensitive receptor there was actually a novel alpha3-containing (not alpha6) subtype (mcclure-begley et al 2012, doi 10.1111/j.1471-4159.2012.07759.x). that's pia doing its job as a discriminator.
is it a drug?
no; like the other alpha6 conotoxins it's a research reagent, not a therapeutic. peptide toxins are hard to turn into drugs (they don't cross the blood-brain barrier well and are degraded), so pia's value is in the lab, mapping which receptors do what. it belongs on this list as one of the key selectivity tools that defined alpha6* pharmacology, not as something anyone takes.
how does it compare to mii and txib?
they're a complementary toolkit. native mii is the founding probe but blocks both alpha3beta2 and alpha6*; engineered mii analogs and pia added alpha6-over-alpha3 selectivity, with pia being the first natural toxin to discriminate them; txib (from conus textile) is a later, highly alpha6beta2*-selective antagonist. researchers often use several together to triangulate receptor identity, since each has slightly different selectivity quirks across species and subtypes.
what did pia help establish about the brain?
it reinforced that alpha6* receptors are a distinct, dopamine-associated population separate from alpha3* receptors, and it let researchers test whether a given 'nicotinic' effect was truly alpha6-mediated. combined with mii analogs and knockout mice, pia is part of the toolkit that built the modern picture of alpha6beta2* receptors as presynaptic gatekeepers of nicotine-evoked dopamine and candidate targets for cessation and parkinson's drugs.
so what's the honest takeaway?
alpha-conotoxin pia is a specialized lab tool, the first ligand to cleanly discriminate alpha6 from alpha3 nicotinic receptors, and it's part of the reason the alpha6* story could be told at all. it's not a supplement, not a medicine, and not something with human dosing; it's a precision reagent that helped define a drug target. included here for completeness and to be honest about where alpha6 selectivity actually came from.